Zydus Lifesciences Limited , a prominent player in the pharmaceutical industry, has successfully secured overwhelming shareholder approval for its ambitious ₹5,000 crore fundraising initiative through a postal ballot process conducted on December 12, 2025.

Postal Ballot Results

The company announced comprehensive results of its postal ballot exercise, with shareholders demonstrating strong confidence in the fundraising proposal. The voting was conducted entirely through remote e-voting in compliance with the Companies Act, 2013 and relevant regulatory guidelines.

The remote e-voting period was conducted from November 13, 2025 (9:00 AM IST) to December 12, 2025 (5:00 PM IST), with Mr. Ashish Doshi of SPANJ Associates serving as the appointed scrutinizer for the voting process. The postal ballot notice was circulated to shareholders on November 11, 2025, with the cut-off date set as November 7, 2025.

Approved Fundraising Framework

The special resolution approved by shareholders provides comprehensive authorization for the Board of Directors to raise funds through multiple instruments and methods. The approved framework allows for significant flexibility in execution.

Fund Utilization Strategy

The company has outlined a strategic approach for utilizing the raised funds, focusing on strengthening its financial position and supporting growth initiatives across multiple areas.

NMPA Approval in China

In addition to the fundraising success, Zydus Lifesciences has received approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg strengths. This marks the company's first approval from the NMPA in China, potentially opening up new market opportunities.

Venlafaxine ER Capsules are indicated for treating Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The medication works by restoring the balance of serotonin and norepinephrine in the brain.

These developments showcase Zydus Lifesciences' commitment to expanding its financial capabilities and global market presence, positioning the company for future growth and innovation in the pharmaceutical sector.

Zydus life science has announced the completion of its postal ballot voting process for a special resolution, with results declared on December 12, 2025. The pharmaceutical company submitted detailed voting results to both BSE Limited and National Stock Exchange of India Limited, fulfilling its regulatory obligations under the SEBI Listing Regulations.

Postal Ballot Process Details

The company facilitated remote e-voting through Central Depository Services (India) Limited platform for its shareholders. The voting process was structured with specific timelines to ensure maximum participation from eligible shareholders.

Voting Results by Category

The postal ballot results show participation across different shareholder categories, with detailed breakdowns of votes polled and voting patterns. The promoter and promoter group category recorded significant participation in the voting process.

Regulatory Compliance

The company has fulfilled its obligations under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed voting results have been submitted along with the Scrutinizer's Report on remote e-voting to ensure transparency and compliance.

The voting results and related documents are being uploaded on the company's official website for public access. This postal ballot process was conducted without a physical Annual General Meeting, as indicated by the "Not Applicable" status for AGM-related parameters in the official documentation.

Corporate Communication

Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), signed the official communication to the stock exchanges. The company maintains its registered office at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), near Vaishnodevi Circle, S.G. Highway, Ahmedabad-382481, Gujarat.